Related Experiment Video
Updated: May 20, 2026
05:32
Povidone Iodine Rectal Preparation at Time of Prostate Needle Biopsy is a Simple and Reproducible Means to Reduce Risk of Procedural Infection
Published on: September 21, 2015
Defining prostate cancer risk before prostate biopsy.
Raj P Pal1, Neil U Maitra, J Kilian Mellon
1University Hospitals of Leicester NHS Trust, Department of Urology, Leicester General Hospital, Leicester, LE5 4PW, UK.
Urologic Oncology
|July 17, 2012
Summary
Current prostate cancer screening methods like PSA and DRE lead to unnecessary biopsies and overdiagnosis of indolent disease. New biomarkers in serum, urine, and imaging show promise for better prostate cancer risk stratification.
Area of Science:
- Urology
- Oncology
- Biomarker Discovery
Background:
- Prostate cancer is the most common cancer diagnosed in men.
- Current prebiopsy risk stratification relies on age, prostate-specific antigen (PSA), and digital rectal examination (DRE).
- Limitations in PSA and DRE lead to unnecessary prostate biopsies and overdiagnosis of indolent prostate cancer.
Purpose of the Study:
- To review the strengths and weaknesses of existing prebiopsy risk stratification methods for prostate cancer.
- To evaluate novel serum, urine, and radiologic biomarkers for improved prostate cancer risk assessment.
Main Methods:
- Literature review of existing prostate cancer prebiopsy risk stratification techniques.
- Evaluation of emerging biomarkers including serum, urine, and imaging-based tests.
- Analysis of biomarker performance in identifying clinically significant prostate cancer.
Main Results:
- Existing methods (age, PSA, DRE) have significant limitations.
- Novel biomarkers demonstrate potential to enhance the accuracy of prostate cancer detection.
- Improved risk stratification can reduce unnecessary biopsies and overdiagnosis.
Conclusions:
- There is a critical need for improved methods to stratify prostate cancer risk before biopsy.
- Emerging biomarkers in serum, urine, and radiology offer promising avenues for enhancing diagnostic accuracy.
- Future research should focus on validating these biomarkers to optimize patient selection for prostate biopsy.
